Treatment Strategies Used in Treating Myelofibrosis: State of the Art

Background: Current drug therapy for myelofibrosis does not alter the natural course of the disease or prolong survival, and allogeneic stem cell transplantation is the only curative treatment modality. For over a decade, the Janus kinase (JAK) inhibitor ruxolitinib has been the standard of care. Mo...

詳細記述

書誌詳細

主要な著者:	Massimo Martino, Martina Pitea, Annalisa Sgarlata, Ilaria Maria Delfino, Francesca Cogliandro, Anna Scopelliti, Violetta Marafioti, Simona Polimeni, Gaetana Porto, Giorgia Policastro, Giovanna Utano, Maria Pellicano, Giovanni Leanza, Caterina Alati
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2024-10-01
シリーズ:	Hematology Reports
主題:	myelofibrosis JAK inhibitors ruxolitinib fedratinib pacritinib momelotinib
オンライン･アクセス:	https://www.mdpi.com/2038-8330/16/4/67
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!